Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more
Windlas Biotech Limited (WINDLAS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.016x
Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has a cash flow conversion efficiency ratio of 0.016x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹66.60 Million) by net assets (₹4.16 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Windlas Biotech Limited - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Windlas Biotech Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Windlas Biotech Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Windlas Biotech Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Micro Systemation AB Series B
LSE:0FBM
|
0.011x |
|
Canyon Resources Ltd
AU:CAY
|
-0.257x |
|
Biosyent Inc.
PINK:BIOYF
|
0.069x |
|
FLITTO Inc
KQ:300080
|
0.343x |
|
Gas Plus S.p.A.
LSE:0EMK
|
N/A |
|
Imagicaaworld Entertainment Limited
NSE:IMAGICAA
|
0.029x |
|
ShareHope Medicine Co Ltd
TWO:8403
|
0.028x |
|
Waratah Minerals Limited
F:0FS0
|
N/A |
Annual Cash Flow Conversion Efficiency for Windlas Biotech Limited (2018–2025)
The table below shows the annual cash flow conversion efficiency of Windlas Biotech Limited from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹5.06 Billion | ₹681.87 Million | 0.135x | -44.33% |
| 2024-03-31 | ₹4.50 Billion | ₹1.09 Billion | 0.242x | +59.79% |
| 2023-03-31 | ₹4.02 Billion | ₹609.65 Million | 0.152x | +555.31% |
| 2022-03-31 | ₹3.95 Billion | ₹91.30 Million | 0.023x | -59.80% |
| 2021-03-31 | ₹1.99 Billion | ₹114.54 Million | 0.058x | -51.77% |
| 2020-03-31 | ₹2.10 Billion | ₹250.06 Million | 0.119x | +23.77% |
| 2019-03-31 | ₹1.94 Billion | ₹186.54 Million | 0.096x | -59.28% |
| 2018-03-31 | ₹1.25 Billion | ₹295.91 Million | 0.237x | -- |